SCHEMBL5986407

SCHEMBL5986407

CNC(=O)OC1CCOC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 1/20 0.40
▸ BAZ2B Q9UIF8 1/20 0.40
▸ CHRM1 P11229 1/20 0.38
▸ BCHE P06276 2/20 0.37
▸ EPHX1 P07099 2/20 0.36
▸ CTSL P07711 3/20 0.34
▸ FASN P49327 4/20 0.33
▸ CTSS P25774 2/20 0.33
▸ MLNR O43193 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CTSD P07339 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP3A5 P20815 1/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ TBXAS1 P24557 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ PDE4A P27815 2/20 0.33
▸ PDE4B Q07343 2/20 0.33
▸ PDE4C Q08493 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13769143 1.00 KAT2B (0.40) KAT2BBAZ2BCHRM1BCHEEPHX1
SCHEMBL15233241 0.88 KAT2B (0.49) KAT2BBAZ2BCHRM1BCHEEPHX1
SCHEMBL15443046 0.84 — —
SCHEMBL25394555 0.81 CTSL (0.38) KAT2BBAZ2BEPHX1CTSLPDE4A
SCHEMBL3999275 0.81 CTSL (0.38) KAT2BBAZ2BEPHX1CTSLPDE4A
SCHEMBL3839876 0.81 CTSL (0.38) KAT2BBAZ2BEPHX1CTSLPDE4A
SCHEMBL31567590 0.81 EPHX1 (0.36) EPHX1CTSLFASNCTSSMLNR
SCHEMBL30934674 0.80 CTSL (0.41) EPHX1CTSLCTSSMLNRABCB11
SCHEMBL7817931 0.80 PDE4D (0.35) EPHX1CTSLFASNCTSSMLNR
SCHEMBL5986951 0.80 EPHX1 (0.59) BCHEEPHX1CTSLPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117897149-A 3, 4-methylenedioxymethamphetamine and related hallucinogens and uses thereof 人类生物科学股份有限公司 2024-04-16 — — CN disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 — — US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 — — US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 — — US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 — — US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 — — US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 — — US disclosed
EP-2447264-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-05-02 — — EP disclosed
EP-2374455-A2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-10-12 — — EP disclosed
US-8022059-B2 Indazole acrylic acid amide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-20 — — US disclosed
US-8022059-B2 Indazole acrylic acid amide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-20 — — US disclosed
EP-2364705-A2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 — — EP disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 — — US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 — — US disclosed
WO-2010150840-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-12-29 — — WO disclosed
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 — — US disclosed
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 — — US disclosed
EP-2192116-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2010-06-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE REN, AGTR1, AGTR2 KAT2B 836/4885BAZ2B 719/4885CHRM1 69/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 KAT2B 1443/4885BAZ2B 1360/4885CHRM1 42/4885
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND KCNH2, KCNH3, KCNJ11 KAT2B 188/4885BAZ2B 869/4885CHRM1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback